6-isothiocyanato-2-hexanol | 158756-39-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 异硫氰酸盐
• 英文名称: 6-isothiocyanato-2-hexanol
• 英文别名: 6-Isothiocyanatohexan-2-ol
• CAS: 158756-39-9
• 化学式: C₇H₁₃NOS
• 分子量: 159.252
• InChiKey: BQYLCVLIDSFGNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Stabilized sulforaphane
  申请人：Dagan Ido Dov

  公开号：US20080176942A1

  公开（公告）日：2008-07-24

  A method of stabilizing sulforaphane is provided. The method includes contacting sulforaphane, or an analog thereof, and a cyclodextrin to form a complex between the sulforaphane, or analog thereof, and the cyclodextrin.

  提供了一种稳定硫代异硫氰酸酯的方法。该方法包括将硫代异硫氰酸酯或其类似物与环糊精接触，以形成硫代异硫氰酸酯或其类似物与环糊精之间的复合物。
• Prevention and Treatment of Oxidative Stress Disorders by compounds which elevate intracellular levels of glutathione or Phase II Detoxification Enzymes
  申请人：Brassica Foundation for Chemoprotection Research, Inc.

  公开号：EP2138170A2

  公开（公告）日：2009-12-30

  The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from photooxidation or oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.

  本发明一般涉及治疗氧化应激紊乱的领域，其方法是施用一种药学有效量的化合物，该化合物能提高动物组织中谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及通过给药有效量的化合物来保护受试者免受光氧化或氧化应激紊乱的领域，该化合物能提高受试者体内谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及一种用于治疗氧化应激紊乱的药物组合物。
• Zusammensetzung zur Hautaufhellung enthaltend Sulforaphan oder Sulforaphen oder deren Derivate
  申请人：Henkel AG & Co. KGaA

  公开号：EP2163238A2

  公开（公告）日：2010-03-17

  Gegenstand der vorliegenden Anmeldung sind kosmetische oder dermatologische Zusammensetzungen zur Aufhellung der Haut, die 8-Hexadecen-1,16-dicarbonsäure und mindestens eine Substanz, ausgewählt aus der Gruppe, bestehend aus Sulforaphan, Sulforaphen, Sulforaphan-Analoga und Sulforaphen-Analoga, enthalten.

  本申请涉及用于美白皮肤的化妆品或皮肤科组合物，该组合物包含 8-十六烯-1,16-二羧酸和至少一种选自由莱菔硫烷、莱菔硫烷、莱菔硫烷类似物和莱菔硫烷类似物组成的组的物质。
• Stabilized Sulforaphane
  申请人：Pharmagra Labs, Inc.

  公开号：EP2532352A1

  公开（公告）日：2012-12-12

  A method of stabilizing sulforaphane is provided. The method includes contacting sulforaphane, or an analog thereof, and a cyclodextrin to form a complex between the sulforaphane, or analog thereof, and the cyclodextrin.

  提供了一种稳定莱菔硫烷的方法。该方法包括将莱菔硫烷或其类似物与环糊精接触，以在莱菔硫烷或其类似物与环糊精之间形成复合物。
• Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase II detoxification enzymes
  申请人：Brassica Foundation for Chemoprotection Research, Inc.

  公开号：EP2698153A1

  公开（公告）日：2014-02-19

  The present invention generally relates to the field of treating oxidative stress disorders, by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracellular levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. The oxidative stress disorders that are treated or prevented are Alzheimer's disase and aging.

  本发明一般涉及治疗氧化应激紊乱的领域，方法是施用一种药学有效量的化合物，该化合物能提高动物组织中谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及通过给药有效量的化合物来保护受试者免受氧化应激紊乱的领域，该化合物能提高受试者体内谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及一种用于治疗氧化应激紊乱的药物组合物。可治疗或预防的氧化应激紊乱包括阿尔茨海默氏症和衰老。